First Human Trial of Oral D-Peptide Drug Targeting Alzheimer's Toxic Oligomers Completed
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Summary
Researchers completed the first human study of Contraloid acetate (also known as PRI-002 or RD2), an oral drug designed to directly break apart the toxic amyloid-beta oligomers believed to drive Alzheimer's disease. Unlike most Alzheimer's drugs that target plaques, Contraloid aims to disassemble the smaller, soluble oligomers that act like prions and spread neurodegeneration. This Phase I single-ascending-dose trial enrolled 40 healthy volunteers to test safety and tolerability across increasing doses. The compound is made of all-D-amino acids, making it resistant to normal protein breakdown, and it can cross the blood-brain barrier. Preclinical results in three different mouse models showed improved cognition and slowed neurodegeneration even with oral dosing, providing the rationale for this human trial.
Detailed Summary
Alzheimer's disease remains one of the most urgent unmet medical needs worldwide, and the field has struggled to produce effective disease-modifying therapies. Most past efforts have focused on clearing amyloid plaques from the brain, but emerging evidence suggests that smaller, soluble amyloid-beta oligomers — not plaques — may be the primary toxic species driving memory loss and neurodegeneration. Contraloid acetate was specifically engineered to address this target.
Contraloid (also called RD2 or PRI-002) is an orally bioavailable all-D-peptide, meaning its amino acids are mirror-image versions of the natural form. This unusual structure makes the drug highly resistant to enzymatic degradation, potentially enabling stable oral dosing. Its proposed mechanism is to directly disassemble toxic amyloid-beta oligomers — which behave similarly to prions in their self-replicating, spreading toxicity — into harmless monomers, without targeting total amyloid-beta levels or plaque burden.
This Phase I single-ascending-dose (SAD) trial was a first-in-human study conducted at a single center. Forty healthy volunteers received escalating oral doses to evaluate safety and tolerability. The study was completed within approximately three months. Preclinical data across three independent transgenic mouse laboratories showed that oral PRI-002 improved cognition and slowed neurodegeneration even under non-preventive treatment conditions, and plasma levels achieved in animals were replicated in humans after single oral dosing.
If the drug demonstrates acceptable safety in this and subsequent trials, it could represent a mechanistically distinct approach to Alzheimer's treatment — one that bypasses the plaque-centric strategy that has failed so many late-stage trials. Its oral availability would also be a major practical advantage over infused biologics.
Key caveats apply: this summary is based on the abstract only, no efficacy or detailed safety results are available here, and Phase I trials in healthy volunteers do not establish whether the drug works in Alzheimer's patients. Much larger and longer trials would be required to demonstrate clinical benefit.
Key Findings
- Contraloid acetate completed a first-in-human Phase I trial in 40 healthy volunteers assessing safety and tolerability.
- The drug targets toxic amyloid-beta oligomers by disassembling them into monomers, not by reducing total amyloid or plaques.
- As an all-D-peptide, Contraloid resists enzymatic breakdown and crosses the blood-brain barrier after oral dosing.
- Plasma levels achieved in preclinical mouse models were replicated in humans after a single oral dose.
- Preclinical studies in three independent labs showed improved cognition and slowed neurodegeneration with oral treatment.
Methodology
This was a single-center, first-in-human, single-ascending-dose Phase I clinical trial enrolling 40 healthy adult volunteers. Participants received escalating oral doses of Contraloid acetate to assess safety and tolerability. The trial ran from April to July 2018 and has been completed.
Study Limitations
This summary is based on the abstract only, as the full trial data are not publicly accessible; detailed safety outcomes, adverse event rates, and pharmacokinetic data are not available here. The trial was conducted exclusively in healthy volunteers, so no conclusions about efficacy or tolerability in Alzheimer's patients can be drawn. Phase I trials are powered for safety, not efficacy, and positive results here do not predict clinical benefit in disease populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.